CAPR CAPRICOR THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1133869 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-11.5%
TTM net income YoY-81.6%
TTM EPS YoY-38.6%
Revenue 3-yr CAGR349.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-191.1%
Net margin-181.7%
FCF margin-184.8%
EBITDA margin-184.7%
Returns
ROE-48.2%
ROA-35.3%
ROIC (approx.)-47.3%
Asset turnover0.19x
Leverage & solvency
Liabilities / assets14.7%
Debt / equity0.00x
Current ratio7.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.99x
Accruals ratio-0.4%
Payout ratio—
Capex / revenue5.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | $22.27M |
| R&D expense | $84.45M | $49.97M |
| SG&A expense | $23.69M | $14.87M |
| Operating income | -$108.14M | -$42.56M |
| Interest expense | $3.05M | $0 |
| Pretax income | -$105.04M | -$40.47M |
| Income tax | $1,600 | $1,600 |
| Net income | -$105.04M | -$40.47M |
| EBITDA | -$106.25M | -$41.14M |
| EPS (basic) | -2.26 | -1.15 |
| EPS (diluted) | -2.26 | -1.15 |
| Weighted avg. shares (diluted) | 46.48M | 35.22M |
| Balance sheet | ||
| Cash & equivalents | $287.85M | $11.29M |
| Short-term investments | $30.28M | $140.23M |
| Current assets | $322.94M | $163.39M |
| PP&E, net | $18.31M | $5.56M |
| Total assets | $355.95M | $170.48M |
| Current liabilities | $35.84M | $21.03M |
| Total liabilities | $50.16M | $25.02M |
| Shareholders' equity | $305.79M | $145.46M |
| Shares outstanding | 57.37M | 45.58M |
| Cash flow statement | ||
| Operating cash flow | -$69.81M | -$40.00M |
| Capital expenditure | $2.90M | $1.17M |
| Free cash flow | -$72.72M | -$41.16M |
| Investing cash flow | $97.48M | -$116.18M |
| Financing cash flow | $248.89M | $152.77M |
| Depreciation & amortization | $1.89M | $1.43M |
| Stock-based compensation | $17.23M | $9.77M |
Free plan shows the latest 2 periods; Pro shows all 20 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.